

ANGEION CORP/MN
Form 10-Q
June 14, 2011

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

for the quarterly period ended April 30, 2011.

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

for the transition period from _____ to _____.

Commission File Number 001-13543

ANGEION CORPORATION

(Exact name of registrant as specified in its charter)

Minnesota

(State or other jurisdiction of
incorporation or organization)

41-1579150

(IRS Employer
Identification No.)

350 Oak Grove Parkway, Saint Paul, Minnesota 55127-8599

(Address of principal executive offices)

Registrant's telephone number, including area code: **(651) 484-4874**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Edgar Filing: ANGEION CORP/MN - Form 10-Q

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of "accelerated filer" and "large accelerated filer" in Rule 12b-2 of the Exchange Act:

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer ☐ Smaller Reporting Company ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐ No ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

As of June 6, 2011, the Company had outstanding 3,800,406 shares of Common Stock, \$0.10 par value.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

<u>Item 1.</u>	<u>Financial Statements</u>	3
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	13
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures about Market Risk</u>	17
<u>Item 4.</u>	<u>Controls and Procedures</u>	18

PART II - OTHER INFORMATION

<u>Item 1.</u>	<u>Legal Proceedings</u>	19
<u>Item 1A.</u>	<u>Risk Factors</u>	19
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	19
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u>	19
<u>Item 4.</u>	<u>Reserved</u>	19
<u>Item 5.</u>	<u>Other Information</u>	19
<u>Item 6.</u>	<u>Exhibits</u>	20

<u>SIGNATURES</u>	21
--------------------------	----

Table of Contents**PART I FINANCIAL INFORMATION****Item 1. Financial Statements.****ANGEION CORPORATION AND SUBSIDIARIES****Consolidated Balance Sheets****April 30, 2011 and October 31, 2010**

(In thousands except share and per share data)

	April 30, 2011 (Unaudited)	October 31, 2010
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 7,792	\$ 6,943
Short-term investments	1,721	2,721
Accounts receivable, net of allowance for doubtful accounts of \$66 and \$100 respectively	4,907	5,221
Inventories, net of obsolescence reserve of \$529 and \$599, respectively	4,047	3,697
Prepaid expenses and other current assets	216	270
Total Current Assets	18,683	18,852
Noncurrent investments	484	722
Property and equipment, net of accumulated depreciation of \$3,638 and \$3,649, respectively	548	528
Intangible assets, net	1,227	1,279
Total Assets	\$ 20,942	\$ 21,381
LIABILITIES AND SHAREHOLDERS EQUITY		
Current Liabilities:		
Accounts payable	\$ 2,152	\$ 1,951
Employee compensation	1,784	2,115
Deferred income	1,670	1,522
Warranty reserve	126	175
Other current liabilities and accrued expenses	367	408
Total Current Liabilities	6,099	6,171
Long-term Liabilities:		
Long-term deferred income and other	808	873
Total Liabilities	6,907	7,044
Commitments and Contingencies		
Shareholders Equity:		
Common Stock, \$0.10 par value, authorized 25,000,000 shares, 3,899,621 and 3,862,113 shares issued and 3,780,160 and 3,747,454 shares outstanding at 2011 and 2010, respectively	378	375
Additional paid-in capital	20,642	20,486
Accumulated deficit	(6,993)	(6,531)
Accumulated other comprehensive income	8	7
Total Shareholders Equity	14,035	14,337
Total Liabilities and Shareholders Equity	\$ 20,942	\$ 21,381

See accompanying notes to consolidated financial statements.

Table of Contents**ANGEION CORPORATION AND SUBSIDIARIES****Consolidated Statements of Operations**

(Unaudited, in thousands except per share data)

	Three Months Ended April 30,		Six Months Ended April 30,	
	2011	2010	2011	2010
Revenues				
Equipment and supply sales	\$ 5,813	\$ 5,961	\$ 11,957	\$ 11,751
Service revenues	987	893	1,896	1,718
	6,800	6,854	13,853	13,469
Cost of revenues				
Cost of equipment and supplies	2,515	2,879	5,231	5,776
Cost of service revenue	392	412	748	763
	2,907	3,291	5,979	6,539
Gross margin	3,893	3,563	7,874	6,930
Operating expenses:				
Selling and marketing	2,079	1,901	4,126	3,843
General and administrative	937	1,051	2,305	2,153
Research and development	902	1,060	1,663	2,099
Amortization of intangibles	105	105	210	210
	4,023	4,117	8,304	8,305
Operating loss	(130)	(554)	(430)	(1,375)
Other expense			22	
Interest income, net	(2)	(3)	(10)	(6)
Loss before income taxes	(128)	(551)	(442)	(1,369)
Provision for income taxes	10	8	20	16
Net loss	\$ (138)	\$ (559)	\$ (462)	\$ (1,385)
Loss per share:				
Basic	\$ (0.04)	\$ (0.13)	\$ (0.12)	\$ (0.33)
Diluted	\$ (0.04)	\$ (0.13)	\$ (0.12)	\$ (0.33)
Weighted average common shares outstanding:				
Basic	3,772	4,151	3,763	4,152
Diluted	3,772	4,151	3,763	4,152

See accompanying notes to consolidated financial statements.

Table of Contents**ANGEION CORPORATION AND SUBSIDIARIES****Consolidated Statements of Cash Flows**

(Unaudited, in thousands)

	Six Months Ended April 30,	
	2011	2010
Cash flows from operating activities:		
Net loss	\$ (462)	\$ (1,385)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	339	392
Stock-based compensation	107	424
(Decrease) increase in allowance for doubtful accounts	(34)	22
(Decrease) increase in inventory obsolescence reserve	(70)	124
Loss on disposal of equipment	22	
Change in operating assets and liabilities:		
Accounts receivable	348	(72)
Inventories	(280)	381
Prepaid expenses and other current assets	54	24
Accounts payable	201	165
Employee compensation	(331)	145
Deferred income	83	87
Warranty reserve	(49)	(2)
Other current liabilities and accrued expenses	(41)	70
Net cash (used in) provided by operating activities	(113)	375
Cash flows from investing activities:		
Sales (purchases) of investments	1,239	(1,724)
Purchases of property and equipment and intangible assets	(329)	(124)
Net cash provided by (used in) investing activities	910	(1,848)
Cash flows from financing activities:		
Proceeds from issuance of common stock under employee stock purchase plan	12	10
Proceeds from the exercise of stock options	48	7
Repurchase of common stock	(8)	(135)
Net cash provided by (used in) financing activities	52	(118)
Net increase (decrease) in cash and cash equivalents	849	(1,591)
Cash and cash equivalents at beginning of period	6,943	11,219
Cash and cash equivalents at end of period	\$ 7,792	\$ 9,628

See accompanying notes to consolidated financial statements.

Table of Contents

ANGEION CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. Basis of Presentation and Description of Business

Angeion Corporation (the "Company"), through its Medical Graphics Corporation subsidiary, designs and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics and New Leaf brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications in healthcare, wellness, and health and fitness.

The consolidated balance sheet as of April 30, 2011, the consolidated statements of operations for the three and six months ended April 30, 2011 and 2010, and consolidated statements of cash flows for the six months ended April 30, 2011 and 2010, and the related information presented in these notes have been prepared by management in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X, without audit. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of results have been included. The consolidated balance sheet at October 31, 2010 was derived from the audited consolidated financial statements as of that date. Operating results for the three and six months ended April 30, 2011 are not necessarily indicative of the results that may be expected for the year ending October 31, 2011. For further information, refer to the consolidated financial statements and notes thereto included in Angeion Corporation's Annual Report on Form 10-K for the year ended October 31, 2010.

Comprehensive loss is a measure of all non-owner changes in shareholders' equity and includes items such as net loss, certain foreign currency translation items, minimum pension liability adjustments and changes in the value of available-for-sale securities. Comprehensive loss for Angeion Corporation was \$138,000 and \$559,000 for the three months ended April 30, 2011 and 2010, respectively, and \$461,000 and \$1,385,000 for the six months ended April 30, 2011 and 2010, respectively.

Preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities made in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Estimates include accounts receivable, product warranty and inventory reserves, and depreciable lives of property, equipment and intangible assets.

The Company determined there were no events subsequent to April 30, 2011, that required recognition or disclosure in these consolidated financial statements, except as disclosed in Notes 3 and 11.

Certain reclassifications of prior year presentations of costs of revenues between the cost of equipment and supplies and the cost of service revenues have been made to conform with current period presentation. The reclassification had no impact on gross margin, net loss or shareholder's equity.

2. Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, transfer of title has occurred or services have been rendered, the selling price is fixed or determinable and collectability is reasonably assured. The Company's products are sold for cash or on unsecured credit terms requiring payment based on the shipment date. Credit terms can vary between customers due to many factors, but are generally, on average, 30-60 days. Revenue, net of discounts, is generally recognized upon shipment or delivery to customers in accordance with written sales terms. Standard sales terms do not include customer acceptance conditions, future credits, rebates, price protection or general rights of return. Although the terms of sales to both domestic customers and international distributors are identical, adherence to these terms is more pervasive with domestic customers than with international customers. In instances when a customer order specifies final acceptance of the system, revenue is deferred until all customer acceptance criteria have been met. Estimated warranty obligations are recorded upon shipment.

Table of Contents

Service contract revenue is based on a stated contractual rate and is deferred and recognized ratably over the service period, which is typically from one to four years. Deferred income associated with service contracts and supplies was \$2,324,000 and \$2,232,000 at April 30, 2011 and October 31, 2010, respectively. Revenue from installation and training services provided to customers is deferred until the service has been performed. The amount of deferred installation and training revenue was \$97,000 and \$125,000 at April 30, 2011 and October 31, 2010, respectively.

When a sale involves multiple deliverables, such as equipment, installation services and training, the amount of the consideration from an arrangement is allocated to each respective element based on the residual method and recognized as revenue when revenue recognition criteria for each element is met. Consideration allocated to delivered equipment is equal to the total arrangement consideration less the fair value of installation and training. The fair value of installation and training services is based on specific objective evidence, including third-party invoices.

No customer accounted for more than 10% of revenues for any of the three- or six-month periods ended April 30, 2011 and 2010.

Advance Payments from Customers

The Company typically does not receive advance payments from its customers in connection with the sale of its products. The Company occasionally enters into an arrangement under which a customer agrees to purchase a large quantity of product that is to be delivered over a period of time. Depending on the size of these arrangements, the Company may negotiate an advance payment from these customers. At April 30, 2011, advance payments from customers aggregated \$42,000 and at October 31, 2010, advance payments from customers aggregated \$16,000. Revenue recognition for customer orders that include advance payments is consistent with the Company's revenue recognition policy described above.

3. Stock-Based Compensation and Stock Options

The Angeion Corporation 2007 Stock Incentive Plan (the "2007 Plan") and the Angeion Corporation 2002 Stock Option Plan (the "2002 Plan") both provide that incentive stock options and nonqualified stock options to purchase shares of common stock may be granted at prices determined by the Compensation Committee, except that the purchase price of incentive stock options may not be less than the fair market value of the stock at date of grant. Under the 2007 Plan, all options expire no later than seven years from the grant date while under the 2002 Plan, all options expire no later than ten years from the grant date. Options under both plans are subject to various vesting schedules. In addition, the 2007 Plan allows the granting of restricted stock awards, stock appreciation rights and performance stock.

Total share-based compensation expense included in the Company's statement of operations for the three months ended April 30, 2011 and 2010 was \$72,000 and \$202,000, respectively and for the six months ended April 30, 2011 and 2010 was \$107,000 and \$424,000, respectively.

Table of Contents**Stock Options**

A summary of our option activity for the six-month period ended April 30, 2011 and 2010 follows:

	For the six months ended April 30, 2011		For the six months ended April 30, 2010	
	Shares	Weighted Average Exercise Price	Shares	Weighted Average Exercise Price
Outstanding at beginning of year	600,573	\$ 6.12	695,787	\$ 6.13
Exercised	(49,500)	2.76	(3,000)	2.00
Expired or cancelled	(124,500)	7.05	(25,382)	7.22
Outstanding at end of period	426,573	\$ 6.24	667,405	\$ 6.11

The following table summarizes information concerning stock options outstanding as of April 30, 2011:

Exercise Prices	Number Outstanding	Weighted Average Remaining Contractual Life	Number Subject to Exercise
\$ 2.00	8,650	2.44	8,650
2.53	17,000	4.38	17,000
5.08	67,500	3.97	67,500
5.16	38,584	4.33	26,176
5.66	46,668	4.05	40,002
6.23	38,500	1.97	38,500
6.60	70,980	3.16	70,980
7.79	41,500	2.44	41,500
7.86	97,191	3.50	97,191
Total	426,573	3.43	407,499

The total intrinsic value of options exercised during the three months ended April 30, 2011 and 2010 was \$83,000 and \$0, respectively. The total intrinsic value of options exercised during the six months ended April 30, 2011 and 2010 was \$105,000 and \$5,400, respectively. The total intrinsic value of options outstanding and exercisable at April 30, 2011 was \$63,000, which was calculated using the closing stock price as of April 30, 2011 less the exercise price of in-the-money options. The Company issues new shares when stock options are exercised. Cash received from the exercise of stock options was \$48,000 and \$7,000 for the six months ended April 30, 2011 and 2010, respectively and there was no related tax benefit realized due to the Company's current tax loss position. Unrecognized compensation expense related to outstanding stock options as of April 30, 2011 was \$27,000, is expected to be recognized over a weighted average period of 0.28 years, and will be adjusted for any future changes in estimated forfeitures.

Valuation Assumptions

The Company uses the Black-Scholes option-pricing model (Black-Scholes model) to determine the fair value of stock options as of the grant date. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company's stock price and expected dividends. The Company did not grant any options during the six months ended April 30, 2011 or 2010.

Table of Contents***Restricted Stock Awards***

Restricted stock awards are awards of common stock that are subject to restrictions on transfer and to a risk of forfeiture if the awardee leaves the Company before the restrictions lapse. The holder of a restricted stock award is generally entitled at all times on and after the date of issuance of the restricted shares to exercise the rights of a shareholder of the Company, including the right to vote the shares. The value of stock awards is established by the market price on the date of its grant.

The following table summarizes the Company's Board of Directors' authorized issuance of restricted stock awards and the awards unvested and outstanding at April 30, 2011:

Award Date	Award Shares	Vesting Period	Outstanding at April 30, 2011
August 28, 2008	74,667	Over three-year period	10,664
June 3, 2009	180,668	Over three-year period	59,552
December 15, 2010	25,000	Over three-year period	25,000
March 16, 2011	10,000	Performance shares, for period through October 31, 2011	10,000
April 11, 2011	14,245	Through October 31, 2011	14,245
	304,580		119,461

As of April 30, 2011, 98,677 of the 304,580 shares awarded have vested, 86,442 were forfeited and 119,461 are outstanding and subject to future vesting. The award issued on March 16, 2011 is a performance share award that would have vested if operating performance criteria for the fiscal year ended October 31, 2011 were achieved. Subsequent to April 30, 2011, the employee recipient of that performance share award terminated employment and (i) that award, (ii) 4,444 of a June 3, 2009 award and (iii) the December 15, 2010 25,000 share award were forfeited. The Company did not grant any restricted stock awards during the six months ended April 30, 2010.

Unrecognized compensation expense related to outstanding restricted stock awards as of April 30, 2011 was \$175,000. The Company expects to recognize this over a weighted average period of 1.82 years.

Employee Stock Purchase Plan

The Angeion Corporation 2003 Employee Stock Purchase Plan ("Stock Plan") allows participating employees to purchase shares of the Company's common stock at a discount through payroll deductions. The Stock Plan is available to all employees subject to certain eligibility requirements. Terms of the Stock Plan provide that participating employees may purchase the Company's common stock on a voluntary after-tax basis. Employees may purchase the Company's common stock at a price that is no less than the lower of 95% (increased effective January 1, 2007) of the fair market value of one share of common stock at the beginning or end of each stock purchase period or phase. The Stock Plan is carried out in six-month phases, with phases beginning on January 1 and July 1 of each calendar year. For the phase that ended on December 31, 2010, employees purchased 2,972 shares at a price of \$3.78 per share. As of April 30, 2011, the Company has withheld approximately \$6,000 from employees participating in the phase that began on January 1, 2011. At April 30, 2011, 51,705 shares of common stock were available for future purchase under the Stock Plan.

Edgar Filing: ANGEION CORP/MN - Form 10-Q

Table of Contents

The following table presents the statement of operations classification of pre-tax stock-based compensation expense recognized for the three and six months ended April 30, 2011 and 2010:

(In thousands)	Three months ended April 30		Six months ended April 30	
	2011	2010	2011	2010
Cost of revenues	\$ 1	\$ 16	\$ 3	\$ 31
Selling and marketing	22	42	46	88
General and administrative	39	122	38	259
Research and development	10	22	20	46
Stock-based compensation expense	72	\$ 202	107	\$ 424

4. Inventories

Inventories consisted of the following at April 30, 2011 and October 31, 2010:

(In thousands)	2011	2010
Raw materials	\$ 986	\$ 977
Work-in-Process	203	233
Finished goods	2,858	2,487
	\$ 4,047	\$ 3,697

5. Intangible Assets

Intangible assets consisted of the following at April 30, 2011 and October 31, 2010:

(In thousands)	2011	2010
Intangible assets:		
Developed technology	\$ 6,835	\$ 6,820
Trademarks (unamortized)	67	62
Capitalized software in progress	357	219
	7,259	7,101
Amortization	(6,032)	(5,822)
	\$ 1,227	\$ 1,279

The intangible assets are being amortized using the straight-line method over the estimated useful lives of the assets that range from seven to ten years. Amortization expense was \$210,000 and \$210,000 for the six months ended April 30, 2011 and 2010, respectively. Estimated amortization expense for each of the succeeding fiscal years based on the intangible assets as of April 30, 2011 is as follows:

(In thousands)	Amortization
Six months ending October 31, 2011	\$ 211
2012	420
	\$ 631

The above table does not include estimated amortization expense for patents and capitalized software of \$529,000, included in developed technology, that are not yet placed in service.

Table of Contents**6. Warranty Reserve**

Sales of the Company's equipment are subject to a warranty obligation. Equipment warranties typically extend for a period of twelve months from the date of installation. Standard warranty terms are included in customer contracts. Under the terms of these warranties, the Company is obligated to repair or replace any components or assemblies that it deems defective in workmanship or materials. The Company reserves the right to reject warranty claims where it determines that failure is due to normal wear, customer modifications, improper maintenance or misuse. The Company maintains a warranty reserve that reflects the estimated expenses that it will incur to honor the warranties on its products. The Company adjusts the warranty reserve based on the number and type of equipment that is subject to warranty, adjusted for the remaining months of warranty coverage. The warranty reserve adjustment reflects the Company's historical warranty experience based on type of equipment. Warranty provisions and claims for the six months ended April 30, 2011 and 2010 were as follows:

(In thousands)	2011	2010
Balance, beginning of period	\$ 175	\$ 143
Warranty provisions based on units sold	84	118
Periodic reserve adjustments	(35)	(4)
Warranty claims	(98)	(116)
Balance, end of period	\$ 126	\$ 141

7. Net Loss per Share

Basic income (loss) per share is computed by dividing net income (loss) by the weighted average shares outstanding during the reporting period. Diluted income (loss) per share is computed similarly to basic income (loss) per share except that in computing income per share the weighted average shares outstanding are increased to include additional shares from the assumed exercise of stock options or warrants and vesting of restricted stock awards, if these events are dilutive. The number of additional shares is calculated by assuming that shares are issued from the exercise of outstanding stock options or warrants and the vesting of outstanding restricted share grants and that the cash proceeds from the exercise and the employment value represented by the unamortized stock-based compensation were used to acquire shares of common stock at the average market price during the reporting period.

Shares used in the loss per share computations are as follows:

(In thousands)	Three months Ended April 30		Six months Ended April 30,	
	2011	2010	2011	2010
Weighted average common shares outstanding basic	3,772	4,151	3,763	4,152
Dilutive effect of stock options and restricted stock awards				
Weighted average common shares outstanding diluted	3,772	4,151	3,763	4,152

8. Income Taxes

The Company has recorded a provision for taxes from operations of \$10,000 and \$8,000 for the three months ended April 30, 2011 and 2010, respectively. For the six-month periods ended April 30, 2011 and 2010, the provision for taxes from operations was \$20,000 and \$16,000, respectively.

At October 31, 2010, the reserve for uncertain tax positions was \$39,000 and did not change during the first two quarters of fiscal 2011. The entire amount of the reserve related to uncertainties regarding income tax nexus with various states in which the Company operates. Included in the reserve is \$14,000 of estimated interest and penalties. The total amount of the reserve has increased the Company's effective tax rate, and would therefore decrease the effective tax rate if removed.

Table of Contents

Estimated interest and penalties related to potential underpayment of income taxes are classified as a component of tax expense in the consolidated statement of operations. The Company does not expect the amount of reserves for uncertain tax positions to change significantly in the next twelve months. Similarly, the Company does not anticipate that the total reserve for uncertain tax positions will significantly change due to the settlement of audits and the expiration of statutes of limitations within the next twelve months.

The Company files a consolidated federal income tax return in the United States Federal jurisdiction and files various combined and separate tax returns in several state and local jurisdictions. With limited exceptions, the Company is no longer subject to United States federal, state and local tax examinations by tax authorities for fiscal years ending prior to November 1, 2008. There is no statute of limitations for assessments related to jurisdictions where the Company may have a nexus but has chosen not to file an income tax return.

The Company had a federal net operating loss (NOL) carry forward at October 31, 2010 of approximately \$16.3 million. This amount is the remaining utilizable NOL carry forward following the application of a limit due to an ownership change under Internal Revenue Code Section 382 that occurred during the fourth quarter of fiscal year 2006. This NOL carry forward is available to offset a portion of taxes payable in future years. If not used, this NOL carry forward will expire in the years 2010 through 2029. The Company also has \$109,000 of alternative minimum tax credit carry forwards that do not have expiration dates. Even though the Company has substantial NOL carry forwards, any income may still be subject to U.S. and State alternative minimum taxes.

The Company has recorded a full valuation allowance against its net deferred tax asset based on its belief that it was more likely than not that the asset would not be realized in the future. Although this determination was made in a prior fiscal year, it is still applicable as of April 30, 2011, and the Company will continue to assess the need for a full valuation allowance in future quarters. Any reduction of the valuation allowance related to post-bankruptcy net operating losses and other deferred tax assets would (i) first affect earnings as a reduction in the provision for taxes and (ii) thereafter, the remaining \$0.9 million would increase additional paid-in capital as these deferred tax assets represent employee stock-based compensation tax deductions included in the Company's net operating losses.

9. Litigation

From time to time, the Company is also subject to claims and lawsuits that have been filed in the ordinary course of business. From time to time, the Company initiates lawsuits against others to enforce patents or to seek collection of debts in the ordinary course of business. There is no material pending or outstanding litigation at the current time.

10. Separation Accrual

During the first quarter of fiscal 2011, the Company incurred a charge of \$418,000 included in general and administrative expenses, consisting of an accrual of separation payments for the former chief executive officer (CEO) of \$451,000 reduced by the effect of forfeitures of previously expensed unvested option and restricted stock award costs.

The following table reconciles 2011 second quarter activity for accrued separation expenses.

(In thousands)	2011
Balance, beginning of period	\$417
Separation payments	(99)
Balance, end of period	\$318

The following table reconciles 2011 year-to-date activity for accrued separation expenses

(In thousands)	2011
Balance, beginning of period	\$
Separation accrual	451
Separation payments	(133)
Balance, end of period	\$318

11. Commitment

On April 15, 2011, the Company's Board of Directors authorized the repurchase of up to \$2,000,000 of its outstanding shares of common stock in the open market or privately negotiated transactions in the period until April 30, 2012. Subsequent to the quarter end, the Board increased this authorization to \$3,000,000 for the same period. No repurchases have been made within this authorization at April 30, 2011.

Table of Contents**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Overview**

The Company, through its Medical Graphics Corporation subsidiary, designs and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics and New Leaf brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications in healthcare, wellness and health and fitness. Revenues consist of equipment and supply sales as well as service revenues. Equipment and supply sales reflect sales of non-invasive cardiorespiratory diagnostic equipment and aftermarket sales of peripherals and supplies. Service revenues consist of revenues from extended service contracts, non-warranty service visits and additional training.

During the first quarter of 2010, Angeion strengthened its marketing and sales teams by adding two new experienced professionals with backgrounds in the medical device market. The Company also initiated a sales and marketing program to establish a network of independent sales representatives and distributors that will market both MedGraphics supplies such as filters and low-cost MedGraphics equipment such as table-top and hand-held spirometers. Angeion also is in the process of establishing an online web store to offer MedGraphics and New Leaf products over the internet.

Total revenues for the second quarter of 2011 were \$6.8 million, a decrease of 0.8% from \$6.9 million in 2010. Operating expenses for the second quarter of 2011 were \$4.0 million, a decrease of 2.3% from the same period in 2010. Net loss for the three months ended April 30, 2011 was \$138,000, or \$0.04 per share, compared to a net loss of \$559,000, or \$0.13 per share, for the same period in 2010.

Total revenues for the six months ended April 30, 2011 were \$13.9 million, an increase of 2.9% from \$13.5 million in 2010. Operating expenses for the six months ended April 30, 2011 were \$8.3 million, unchanged from the same period in 2010. Net loss for the six months ended April 30, 2011 was \$462,000, or \$0.12 per share, compared to a net loss of \$1.4 million, or \$0.33 per share, for the same period in 2010.

Results of Operations

The following table contains selected information from the Company's consolidated statements of operations, expressed as a percentage of revenues:

	Three Months Ended April 30,		Six Months Ended April 30,	
	2011	2010	2011	2010
Revenues	100.0%	100.0%	100.0%	100.0%
Cost of revenues	42.7	48.0	43.2	48.5
Gross margin	57.3	52.0	56.8	51.5
Operating expenses:				
Selling and marketing	30.6	27.7	29.8	28.5
General and administrative	13.8	15.3	16.6	16.0
Research and development	13.3	15.5	12.0	15.6
Amortization of intangibles	1.5	1.6	1.5	1.6
	59.2	60.1	59.9	61.7
Operating income (loss)	(1.9)	(8.1)	(3.1)	(10.2)
Other expense			0.2	
Interest income	0.0	0.0	(0.1)	0.0
Income (loss) before taxes	(1.9)	(8.1)	(3.2)	(10.2)
Provision for taxes	0.1	0.1	0.1	0.1
Net income (loss)	(2.0%)	(8.2%)	(3.3%)	(10.3%)

Table of Contents

The following paragraphs discuss the Company's performance for the three- and six-month periods ended April 30, 2011 and 2010.

Revenue

Total revenue for the three and six months ended April 30, 2011, increased (decreased) by (0.8%) and 2.9%, respectively, compared to the same periods in 2010. Domestic revenue for the three months ended April 30, 2011 increased by 1.4% and international revenue decreased by 9.0% from prior year period levels, with decreases in international revenues broadly based across all geographic regions, except the Americas, which accounted for modest increases.

The increase in revenue of \$0.4 million for the six-month period ended April 30, 2011 was primarily due to domestic performance offset by reduced second quarter international sales due to the general economic conditions therein.

Gross Margin

Gross margin percentage for the three and six months ended April 30, 2011 increased to 57.3% and 56.8% of revenue, respectively, compared to 52.0% and 51.5%, respectively, for the same periods in 2010. Gross margin percentage for the three- and six-month periods increased as a result of continuing manufacturing efficiencies following right sizing actions taken in the third quarter of fiscal 2010. We expect that the effects of manufacturing efficiencies at these sales levels will continue in the remaining fiscal 2011 quarters.

Selling and Marketing

Selling and marketing expenses increased to \$2.1 million and \$4.1 million, respectively, for the three- and six-month periods ended April 30, 2011 from \$1.9 million and \$3.8 million for the same periods in 2010. Expenses for the three-month period ended April 30, 2011 increased from personnel transfers from research and development to sales and marketing roles by \$98,000 and decreased from incentive programs by \$30,000. Expenses for the six-month period ended April 30, 2011 increased from personnel additions and transfers from research and development roles by \$73,000 and \$178,000, respectively and decreased from incentive programs by \$30,000. Stock-based compensation expenses decreased by \$20,000 and \$42,000 for the three and six months ended April 30, 2011, respectively, compared to the prior year periods.

General and Administrative

For the three months ended April 30, 2011, general and administrative expenses decreased by \$114,000, or 10.8%, compared to the same period in 2010, due primarily to \$39,000 in decreased compensation related costs resulting from administrative staff changes in fiscal 2010 and 2011 and \$83,000 in reduced stock-based compensation related to employee and board of director changes occurring in the second half of fiscal 2010.

For the six months ended April 30, 2011, general and administrative expenses increased \$152,000 compared to the same period in 2010. This increase included a charge of \$418,000 (net of a \$33,000 offset for reduction in stock-based compensation) related to the separation of our former chief executive officer in the 2011 first fiscal quarter. The general and administrative costs without this charge decreased \$266,000, due primarily to \$106,000 in decreased compensation related costs resulting from administrative staff changes in fiscal 2010 and 2011 and \$188,000 in reduced stock-based compensation related to other employee and board of director changes occurring in the second half of fiscal 2010. Certain of these cost reductions are not expected to be ongoing as additional hires to refill open positions have occurred following the close of the 2011 fiscal second quarter.

Table of Contents

Research and Development

Research and development expenses for the three and six months ended April 30, 2011 were \$0.9 and \$1.7 million, respectively, compared to \$1.1 and \$2.1 million, respectively, for the same periods in 2010.

Expense reductions in the three and six months ended April 30, 2011 compared to the same periods in 2010 were primarily for roles transferred to selling and marketing and the effects of the product development expense cycle. In the 2010 fiscal first and second quarter, the Company expensed all expenditures related to its ongoing research and development project to migrate the MedGraphics and New Leaf products operating software platform to next-generation technologies, given the planning and development nature of these expenditures. Staff personnel and consulting time related to planning and development expenses were reduced by \$98,000 and \$189,000 in the three and six months ended April 30, 2011, respectively, offset by \$55,000 of recruiting costs in the second quarter of fiscal 2011 related to the addition of a vice president of engineering who was hired after quarter end. In addition, approximately \$48,000 and \$138,000 of incurred costs were capitalized in fiscal 2011 as software-in-progress for the three and six months ended April 30, 2011, respectively, since these projects have achieved technological feasibility. As we have discussed previously, while this capitalized cost spending affects our cash flows and to a lesser extent our net loss, we believe that these investments provide the foundation for a future product pipeline of new integrated patient care and consumer health programs that will deliver sustained growth. The majority of these software projects will be ongoing until late fiscal 2011, with a portion continuing into fiscal 2012, when we expect the benefits of this effort will become available for use in our product offerings.

Amortization of Intangibles

Amortization of developed technology was \$105,000 and \$210,000, respectively, for the three and six months ended April 30, 2011 and 2010, respectively.

Interest Income

Interest income for the three- and six-month periods ended April 30, 2011 (decreased)/increased to (\$1,000) and \$4,000, respectively, compared to the same periods in 2010. The Company maintains the highest degree of safety in its investments, while avoiding the investment risk of other forms of available investments, and has purchased short and medium term bank certificates of deposit and United States Treasury Bills to improve its interest return as rates have declined to historic low rates in the past several quarters.

Provision for Income Taxes

The Company is required to present the provision for taxes as if it were fully taxable in accordance with Financial Accountings Standards Board (FASB) Accounting Standards Codification 852-740. In prior years, the Company utilized its pre-emergence bankruptcy NOLs in the calculation of its income taxes payable but is still required to pay U.S. and State alternative minimum taxes (AMT) in certain jurisdictions, even though it has substantial federal and state NOL carry forwards available. During the three and six month periods ended April 30, 2011 and 2010, the Company did not use any tax benefits related to pre-emergence bankruptcy NOLs. See note 8 to the consolidated financial statements, Income Taxes, in this Form 10-Q for additional discussion of the accounting for income taxes.

Table of Contents

Liquidity and Capital Resources

The Company has financed its liquidity needs over the last several years through revenue generated by its operations.

The Company had cash, cash equivalents and investments of \$10.0 million and working capital of \$12.6 million as of April 30, 2011. During the first half of fiscal 2011, the Company reported a net loss of \$462,000. However, cash flows used in operating activities were \$113,000, primarily due to reductions of \$348,000 in accounts receivables, increases in inventory of \$280,000, decreases of \$47,000 in accounts payable, accrued employee compensation and deferred income, collectively resulting from working capital management and seasonal payments, together with the add-back of non-cash expenses totaling \$446,000 for depreciation, amortization and stock-based compensation.

For the six months ended April 30, 2011, the Company used \$329,000 in cash for the purchase of property and equipment and intangible assets and generated \$1,239,000 from the sale of investments.

The Company generated cash from financing activities of \$52,000 during the six months ended April 30, 2011, which primarily consisted of \$60,000 proceeds from (i) the exercise of stock options and (ii) the issuance of shares under the Employee Stock Purchase Plan.

During the second quarter of fiscal 2011, the Company announced its Board of Directors' authorization to repurchase up to \$2,000,000 worth of its outstanding shares in the open market or in privately negotiated transactions, from time to time, in the period until April 30, 2012. Subsequent to the quarter end, the Board increased this authorization to \$3,000,000 for the same period.

The Company believes that its liquidity and capital resource needs for fiscal 2011 and the next twelve months will be met through its current cash, cash equivalents and investments, as well as cash flows resulting from operations. In addition, as previously announced, the Company has developed a market-focused approach to strategically leverage the strength of its MedGraphics brand and worldwide selling and distribution capability. The Company may also use some of its cash and capital resources in the acquisition of new businesses, technologies or products that complement its existing products. Specifically, from time to time, the Company engages in discussions with other companies concerning the development or acquisition of new or complementary products. Although the Company is continuing to look at a number of these opportunities, it currently has no agreements or understandings with any of these third parties.

Table of Contents

Forward Looking Statements.

The discussion above contains forward-looking statements about Angeion's future financial results and business prospects that by their nature involve substantial risks and uncertainties. You can identify these statements by the use of words such as anticipate, believe, estimate, expect, project, intend, plan, will, target, and other words and terms of similar meaning in connection with any discussion of future operations, financial performance or business plans or prospects. Our actual results may differ materially depending on a variety of factors including: (1) national and worldwide economic and capital market conditions; (2) continuing cost-containment efforts in our hospital, clinic, and office market; (3) any changes in the patterns of medical reimbursement that may result from national healthcare reform; (4) our ability to successfully operate our business, including successfully converting our increasing research and development expenditures into new and improved cardiorespiratory diagnostic products and services and selling these products and services under the MedGraphics and New Leaf brand names into existing and new markets; (5) our ability to complete our software development initiatives and migrate our MedGraphics and New Leaf platforms to a next generation technology; (6) our ability to maintain our cost structure at a level that is appropriate to our near-to mid-term revenue expectations and that will enable us to increase revenues and profitability as opportunities develop; (7) our ability to achieve constant margins for our products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers; (8) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (9) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products; (10) our ability to defend our existing intellectual property and obtain protection for intellectual property we develop in the future; (11) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures; (12) our dependence on third-party vendors; and (13) the ability of new members of our senior management to make a successful transition into their new roles and for all members of senior management to ultimately develop and implement a strategic plan. Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the above discussion is qualified in its entirety by, the other risk factors that are described from time to time in the Company's Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2010.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

None.

Table of Contents

Item 4. Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures

Management, with the participation of the Company's interim chief executive officer, Gregg O. Lehman, and chief financial officer, Robert M. Wolf, has evaluated the effectiveness of the design and operation of the disclosure controls and procedures, as defined in Rules 13a-15(e) under the Securities Exchange Act of 1934, as of the end of the period covered by this report. Management has concluded that the Company's disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports that the Company files under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that the disclosure controls are also effective to ensure that information required to be disclosed in the Company's Exchange Act reports is accumulated and communicated to management, including the chief executive officer and principal accounting officer, to allow timely decisions regarding required disclosure.

(b) Changes in Internal Controls

There have been no changes in internal control over financial reporting that occurred during the second fiscal quarter of 2011 that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

Table of Contents**PART II OTHER INFORMATION****Item 1. Legal Proceedings.**

From time to time, the Company is also subject to claims and lawsuits that have been filed in the ordinary course of business. From time to time, the Company initiates lawsuits against others to enforce patents or to seek collection of debts in the ordinary course of business. There is no material pending or outstanding litigation at the current time.

Item 1A. Risk Factors

We described the most significant risk factors applicable to the Company in Part I, Item 1A Risk Factors of our Annual Report on Form 10-K for the year ended October 31, 2010. We believe there have been no material changes from the risk factors disclosed in that Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In the three months ended April 30, 2011, the Company repurchased shares of its common stock, as follows:

Period	Issuer Purchases of Equity Securities ⁽¹⁾		(c) Total Number of Shares Purchased as Part of Publicly Announced Program	(d) Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
	(a) Total Number of Shares Purchased	(b) Average Price Paid per Share		
February 1-28, 2011				
March 1-31, 2011 ⁽²⁾	1,658	\$ 4.89		
April 1-30, 2011				
Total	1,658	\$ 4.89		\$ 3,000,000

⁽¹⁾On April 15, 2011, the Company announced that its Board of Directors had authorized an extension to its stock repurchase program under which Angeion may repurchase up to and additional \$2,000,000 of its outstanding shares of common stock in the open market or in privately negotiated transactions, over a twelve-month period ending April 30, 2012. On May 26, 2011, the Company announced this amount had been increased to \$3,000,000.

⁽²⁾The Company withheld 1,658 shares for the payment of required payroll withholding taxes in connection with the March 22, 2011 exercise of 10,500 outstanding stock options originally granted September 15, 2005 to an employee. The value of these shares on March 22, 2011 was \$4.89 per share.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Reserved**Item 5. Other Information.**

None.

Table of Contents

Item 6. Exhibits.

- 31. Certifications pursuant to Rules 13a-14 and 15d-14 of the Exchange Act.
- 32. Certifications pursuant to 18 U.S.C. § 1350.

20

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ANGEION CORPORATION
(Registrant)

June 14, 2011

By: /s/ Gregg O. Lehman
Gregg O. Lehman
Interim Chief Executive Officer

June 14, 2011

By: /s/ Robert M. Wolf
Robert M. Wolf
Chief Financial Officer